GlaxoSmithKline (GSK) Withdrawals FDA App for Breast Cancer Treatment Tykerb

Article Stock Quotes (1) Comments (0)

GlaxoSmithKline plc (NYSE: GSK) said it has withdrawn a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Tykerb (lapatinib) in combination with trastuzumab for the treatment of patients with HER2 (ErbB2)-positive metastatic breast cancer who have received prior trastuzumab therapy. Regulatory reviews are ongoing in the European Union and other regions.

“Our discussions with FDA highlighted questions that could not be addressed with the data currently available.” said Rafael Amado, Head of Oncology R&D for GlaxoSmithKline. “We have decided to withdraw our application in the US with the intent to wait for ongoing studies testing the combination of lapatinib with trastuzumab.”

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
• Acacia Research (ACTG) Enters Settlement with Red Hat (RHT)
• Tessera (TSRA), Starboard Reach Agreement Over Board Composition

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?